You are viewing: Italy Next-generation Sequencing Market analysis

The Italy Next-generation Sequencing Market was valued at $196.2 Million in 2026 and projected to reach to $341.1 Million by 2031, representing a compound annual growth rate of 11.7%. Italy's next-generation sequencing market is positioned for sustained growth through 2031, driven by increasing healthcare expenditure on advanced diagnostics and growing adoption of genomic medicine in clinical practice.

Italy Next-generation Sequencing Market Trends and Insights

  • This growth trajectory reflects Italy's increasing adoption of advanced genomic technologies across clinical diagnostics, research institutions, and personalized medicine applications.
  • Italy's healthcare infrastructure and investment in precision medicine initiatives are driving demand for NGS solutions among hospitals, diagnostic laboratories, and academic centers. The Italian NGS market benefits from rising prevalence of genetic disorders, cancer incidence, and growing awareness of genomic testing among healthcare providers and patients.
  • Italy's regulatory environment and European Union compliance frameworks support the integration of NGS into standard clinical workflows.
  • Between 2026 and 2031, Italy is expected to see accelerated adoption driven by technological improvements, cost reduction in sequencing platforms, and expanded reimbursement policies that make NGS more accessible across the country's healthcare system..

Key Market Statistics

  • CAGR (2026-2031) 11.7% CAGR
  • Market Size, 2026 ~USD 196.2 Million
  • Forecast, 2031 ~USD 341.1 Million
  • Country Italy

Italy Next-generation Sequencing Market Overview

Market Valuation Growth :

Italy's NGS market is valued at $196.2 million in 2026 and is projected to reach $341.1 million by 2031, representing a robust 11.7% CAGR over the forecast period.

Clinical Diagnostics Expansion :

Italian healthcare institutions are increasingly integrating NGS technologies into routine clinical diagnostics, particularly for cancer genomics, rare disease identification, and infectious disease monitoring.

Personalized Medicine Adoption :

Italy's investment in precision medicine initiatives is driving demand for NGS applications in pharmacogenomics and treatment stratification across major Italian hospitals and research centers.

Research Infrastructure Development :

Italian academic institutions and biotech companies are expanding genomic research capabilities, supported by EU funding and national healthcare initiatives focused on advanced molecular diagnostics.

Italy Next-generation Sequencing Market Dynamics

  • The Italian healthcare system's emphasis on precision medicine and early disease detection is accelerating NGS technology integration across major medical centers and diagnostic laboratories. Key growth drivers include rising cancer incidence requiring genomic profiling, expanding rare disease diagnosis programs, and strengthening collaborations between Italian research institutions and international genomic consortia.
  • Government support for healthcare innovation and EU-backed precision medicine initiatives will further accelerate market expansion, positioning Italy as a significant NGS market within Southern Europe..

Related Ecosystem

Key Takeaways

  • Italy's NGS market is valued at $196.2 million in 2026 and will grow to $341.1 million by 2031, representing an 11.7% CAGR.
  • Italy's adoption of NGS is driven by increasing genetic disorder prevalence, cancer diagnostics demand, and precision medicine initiatives.
  • Italy's EU regulatory framework and healthcare infrastructure support seamless integration of NGS into clinical diagnostic workflows.
  • Cost reduction in sequencing technologies and expanded reimbursement policies will accelerate Italy's NGS market penetration through 2031.

Next-generation Sequencing Market Report Scope

Report Metric Details
Base Year 2026
Fastest Growing Segment SERVICES (Offering)
Forecast Period 2026–2031
Growth Rate CAGR of 14.5% from 2026 to 2031
Largest Segment PRODUCTS (Offering)
Market Size Base Year (Billions) ~USD 13.93 (2026)
Revenue Forecast (Billions) ~USD 27.41 (2031)
Segments Covered Offering, Type, Technology, Workflow, End User, Application

Italy Next-generation Sequencing Market Report Segmentation

6 segment dimensions are covered across the global market.

By Offering

  • Products
  • Services

By Type

  • Bioinformatics Tools
  • Cancer Diagnostics
  • Consumables
  • Data Analysis Services
  • Data Analysis Software & Workbenches
  • Data Storage & Management Services
  • Data Visualization & Interpretation Services
  • Data Visualization Tools
  • Illumina
  • Infectious Disease Diagnostics
  • Library Preparation & Target Enrichment Services
  • Library Preparation Kits & Reagents
  • Library Preparation Platforms
  • Miniseq/Iseq
  • Miseq/ Miseq I100
  • Nextseq 1K/2K And 550
  • Novaseq 6000
  • Novaseq Series (X/ X Plus)
  • Other Bioinformatics Tools
  • Other Consumables
  • Other Diagnostic Applications
  • Other Drug Discovery & Development Applications
  • Other Sequencing Platforms
  • Oxford Nanopore Technologies
  • Pacbio
  • Pharmacogenomics
  • Platforms
  • Quality Control Services
  • Reproductive Health Diagnostics
  • Sample Preparation Services
  • Sequencing Kits & Reagents
  • Sequencing Platforms
  • Thermo Fisher Scientific

By Technology

  • Ion Semiconductor Sequencing
  • Nanopore Sequencing
  • Other Sequencing Technologies
  • Sequencing By Synthesis
  • Smrt Sequencing

By Workflow

  • Data Analysis
  • Presequencing
  • Sequencing

By End User

  • Academic & Research Institutes
  • Clinical & Diagnostic Laboratories
  • Hospitals & Clinical Laboratories
  • Other End Users
  • Pharmaceutical & Biotechnology Companies

By Application

  • Agriculture & Animal Research
  • Diagnostics
  • Drug Discovery & Development
  • Other Applications

Target Audience

  • Italian Healthcare Providers : Hospital networks and diagnostic laboratories need Italy-specific market data to evaluate NGS technology investments, benchmark adoption rates, and plan genomic medicine service expansion.
  • NGS Equipment & Service Vendors : Manufacturers and service providers require detailed Italian market intelligence to develop localized go-to-market strategies, identify key accounts, and forecast revenue potential in the Italian healthcare system.
  • Biotech & Genomics Companies : Italian and international biotech firms need market insights to assess commercialization opportunities, understand competitive dynamics, and identify partnership or acquisition targets in Italy's NGS ecosystem.
  • Healthcare Investors & PE Firms : Investment professionals evaluating opportunities in Italian healthcare require validated market data, growth projections, and competitive analysis to support investment thesis development and due diligence.
  • Healthcare Policy & Government Bodies : Italian health authorities and policy makers need market intelligence to inform precision medicine initiatives, healthcare budget allocation, and regulatory framework development for genomic diagnostics.

Key Companies in the Italy Next-generation Sequencing Market

CompanyHQOwnershipStrongest segments
DNA LINKSouth KoreaPublic CompanyWhole genome and De Novo sequencing,Whole exome and targeted sequencing,Transcriptome and single-cell RNA sequencing,
WUXI APPTECChinaPublic CompanyWuXi Chemistry (small molecules, oligos, peptides, conjugates),WuXi Testing (toxicology, DMPK, bioanalytical, other lab testing),WuXi Biology (discovery biology, target-to-candidate services),
THERAGEN ETEX CO., LTD.South KoreaPublic CompanyCirculatory and metabolic drugs,Respiratory and digestive therapies,Antibiotics and antifungals,
SYSMEX CORPORATIONJapanPublic CompanyHematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx),Coagulation diagnostics,Blood gas, electrolyte, and urinalysis systems,
GENOMICS BIOSCI & TECH. CO., LTD.TaiwanPublic CompanyClinical testing (reproductive health and cancer),Sequencing, synthesis, genomics and proteomics services,CDMO (contract development and manufacturing),
INTEGRAGEN SAFrancePublic CompanyGenomic pharma and research sequencing services (oncology and rare disease),MERCURY oncology interpretation platform,Galileo RNA-Seq exploration and related analytics,
CENTOGENE AGGermanyPublic CompanyGenetic sequencing and diagnostics (WES, WGS, NGS assays including NEW CentoGenome),Multiomic solutions (CENTOGENE MOx 2.0 and biochemical/RNA integration),Pharma solutions (target/drug screening, clinical development, market access, patient recruitment),
PERSONALIS, INC.United StatesPublic CompanyPharma and biopharma services (ImmunoID NeXT, WES/WGS, translational research and clinical trials),MRD and therapy monitoring (NeXT Personal, NeXT Personal Dx),Clinical tumor profiling and Dx (NeXT Dx and related physician-ordered tests),
BIOMERIEUX S.A.FrancePublic CompanyClinical microbiology (culture media, VITEK, VIRTUO, ETEST, API, VITEK REVEAL),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS),Immunoassays and CLIA (VIDAS, Hybiome),
ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Array-based instruments and consumables,
THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response and infectious disease diagnostics,Oncology and sexual & reproductive health assays,
DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and related solutions),Life Sciences (instruments, genomics, and reagents),Diagnostics (clinical instruments and consumables),
REVVITYUnited StatesPublic CompanyDiagnostics instruments and reagents (prenatal, neonatal, infectious disease, specialty immunodiagnostics),Life science reagents and assay platforms (immunology, cell analysis, proteomics),Genomic workflows and NGS-related tools,
EUROFINS SCIENTIFICLuxembourgPublic CompanyFood and Feed Testing, Assurance, and Certification,Environment and Maritime Testing,Biopharma Testing and PSS Insourcing,
PACBIOUnited StatesPublic CompanyLong-read instruments (Revio, Sequel, Vega),Long-read consumables and SMRT reagents,Short-read sequencing (Onso) and related consumables,
OXFORD NANOPORE TECHNOLOGIES PLCUnited KingdomPublic CompanyPromethION systems and consumables,MinION and portable platforms,GridION and mid-throughput systems,
TAKARA BIO INC.JapanPrivate CompanyGenetic and cellular research reagents,Instruments (PCR and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
BDUnited StatesPublic CompanyMedical Essentials (vascular access, syringes, needles, sharps, enteral),Connected Care (infusion therapy, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery systems),
10X GENOMICSUnited StatesPublic CompanyChromium instruments,Chromium consumables & kits (incl. QuantumScale),Visium spatial platform (instruments, slides, assays),

DNA LINK

DNA LINK is a South Korean public company founded in 2000 with 84 employees, operating in the genomics and biotechnology sector.

WUXI APPTEC

WUXI APPTEC is a Chinese public company founded in 2000 with 33,834 employees, providing pharmaceutical research and development services.

THERAGEN ETEX CO., LTD.

THERAGEN ETEX CO., LTD. is a South Korean public company founded in 1987 with 224 employees, specializing in genomics and genetic testing.

SYSMEX CORPORATION

SYSMEX CORPORATION is a Japanese public company founded in 1968 with 10,861 employees, providing diagnostic and laboratory equipment solutions.

GENOMICS BIOSCI & TECH. CO., LTD.

GENOMICS BIOSCI & TECH. CO., LTD. is a Taiwanese public company founded in 2001, operating in the genomics and biotechnology industry.

INTEGRAGEN SA

INTEGRAGEN SA is a French public company founded in 2000 with 37 employees, specializing in genomics and genetic analysis.

CENTOGENE AG

CENTOGENE AG is a German public company founded in 2006 with 384 employees, providing genetic testing and diagnostic services.

PERSONALIS, INC.

PERSONALIS, INC. is a United States-based public company founded in 2011 with 260 employees, specializing in genomic sequencing and analysis.

BIOMERIEUX S.A.

BIOMERIEUX S.A. is a French public company founded in 1963 with 14,894 employees, providing in vitro diagnostics and microbiology solutions.

ILLUMINA, INC.

ILLUMINA, INC. is a United States-based public company founded in 1998 with 8,625 employees, a leading provider of DNA sequencing and genetic analysis platforms.

THERMO FISHER SCIENTIFIC INC.

THERMO FISHER SCIENTIFIC INC. is a United States-based public company founded in 1956 with 125,000 employees, providing life sciences research and diagnostic products and services.

AGILENT TECHNOLOGIES, INC.

AGILENT TECHNOLOGIES, INC. is a United States-based public company founded in 1999 with 18,000 employees, offering analytical instruments and life sciences solutions.

QIAGEN

QIAGEN is a Netherlands-based public company founded in 1984 with 5,500 employees, providing molecular diagnostics and life sciences research tools.

DANAHER CORPORATION

DANAHER CORPORATION is a United States-based public company founded in 1969 with 59,000 employees, operating a diversified conglomerate including life sciences and diagnostics.

REVVITY

REVVITY is a United States-based public company founded in 1937 with 11,000 employees, providing analytical instruments and life sciences solutions.

EUROFINS SCIENTIFIC

EUROFINS SCIENTIFIC is a Luxembourg-based public company founded in 1987 with 65,694 employees, providing laboratory testing and scientific services globally.

PACBIO

PACBIO is a United States-based public company founded in 2000 with 485 employees, specializing in long-read DNA sequencing technology.

OXFORD NANOPORE TECHNOLOGIES PLC

OXFORD NANOPORE TECHNOLOGIES PLC is a United Kingdom-based public company founded in 2005 with 1,316 employees, developing nanopore-based DNA and RNA sequencing technology.

TAKARA BIO INC.

TAKARA BIO INC. is a Japanese private company founded in 2002 with 1,779 employees, providing biotechnology products and services for research and diagnostics.

BD

BD is a United States-based public company founded in 1897 with 72,000 employees, providing medical devices, diagnostics, and life sciences solutions.

10X GENOMICS

10X GENOMICS is a United States-based public company founded in 2012 with 1,178 employees, developing single-cell and spatial genomics technologies.

Reasons to Buy this Report

  • Italy-Specific Market Sizing : Access precise valuation data for Italy's NGS market with validated 2026-2031 forecasts, enabling accurate investment planning and market entry strategies tailored to Italian healthcare economics.
  • Clinical Adoption Insights : Understand how Italian hospitals and diagnostic labs are implementing NGS technologies, including adoption rates across different clinical specialties and regional healthcare variations.
  • Competitive Landscape Analysis : Identify key players operating in Italy's NGS market, their market positioning, and strategic initiatives specific to Italian healthcare regulations and reimbursement frameworks.
  • Regulatory & Reimbursement Pathways : Gain insights into Italian healthcare approval processes, reimbursement policies, and regulatory requirements that directly impact NGS product commercialization and market access.
  • Growth Opportunity Mapping : Discover high-potential segments within Italy's NGS market, including emerging applications in rare diseases, oncology, and infectious disease diagnostics with quantified growth projections.

Frequently asked questions

What is the current size of Italy's NGS market?

Italy's next-generation sequencing market is valued at $196.2 million in 2026 and is projected to reach $341.1 million by 2031.

What is the growth rate of Italy's NGS market?

Italy's NGS market is expected to grow at a compound annual growth rate (CAGR) of 11.7% from 2026 to 2031.

What factors are driving growth in Italy's NGS market?

Italy's NGS market growth is driven by rising genetic disorder prevalence, increased cancer diagnostics demand, precision medicine adoption, technological improvements, cost reduction, and expanded reimbursement policies.

Which sectors in Italy are adopting NGS technology?

Italy's hospitals, diagnostic laboratories, academic research institutions, and clinical centers are actively adopting NGS for genetic testing, cancer diagnostics, and personalized medicine applications.

How does Italy's regulatory environment support NGS adoption?

Italy's alignment with European Union compliance frameworks and regulatory standards facilitates the integration of NGS into standard clinical workflows and diagnostic practices.

RESEARCH METHODOLOGY

This study of the next-generation sequencing market relied on secondary sources, directories, and databases to gather pertinent information. To collect and validate key qualitative and quantitative data and to evaluate market growth prospects, in-depth interviews were conducted with numerous primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives from key market players, and industry consultants. After estimating the next-generation sequencing market using several research strategies, the final market size was derived by triangulating data from primary research.

Secondary Research

Secondary sources for this research study include publications from government sources. These include the Centers for Disease Control and Prevention (CDC), the US Food and Drug Administration (FDA), the World Health Organization (WHO), the American Cancer Society (ACS), the National Center for Biotechnology Information (NCBI), the National Institutes of Health (NIH), the National Human Genome Research Institute (NHGRI), the International Agency for Research on Cancer (IARC), the National Institute for Infectious Diseases (IRCCS), the Association for Clinical Genomic Science (ACGS), the American Society of Human Genetics (ASHG), the European Society of Human Genetics (ESHG), the Asia Pacific Society of Human Genetics (APSHG), Nature Reviews Genetics, Nature Methods, the Biotechnology and Biological Sciences Research Council (BBSRC), the Organisation for Economic Co-operation and Development (OECD), Genome Research, the National Cancer Institute (NCI), the European Medicines Agency (EMA), the Population Health Research Institute (PHRI), PubMed, the World Bank, and the World Health Organization (WHO), among others. Secondary sources also included corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data were collected and analyzed to determine the overall size of the global next-generation sequencing market, which was validated through primary research.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge of the global next-generation sequencing market through secondary research. Several primary interviews were conducted with market experts from the supply side, including C-level and D-level executives, operational managers, and marketing & sales managers at key manufacturers, distributors, and channel partners of companies providing NGS; and from the demand side, including personnel from academic & research institutes, hospitals, clinics and diagnostic labs, pharmaceutical & biopharmaceutical industries, CROs, and other end users. These interviews were conducted across six major regions, including North America, Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

Next Generation Sequencing Market 
 Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both, the top-down and bottom-up approaches were used to estimate and validate the total size of the next-generation sequencing market. These methods were also used extensively to estimate the size of various subsegments within the market. The research methodology for estimating market size includes the following.

Next Generation Sequencing Market Top Down and Bottom Up Approach

Data Triangulation

To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Next-generation sequencing (NGS) refers to non-Sanger-based, high-throughput DNA sequencing technologies. These technologies sequence DNA strands simultaneously, yielding substantially higher throughput and reducing the need for fragment-cloning methods often used in Sanger genome sequencing. NGS is fundamentally based on sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing.

Key Stakeholders

  • NGS instrument manufacturers, vendors, and distributors
  • NGS service providers
  • NGS bioinformatics/data analysis companies
  • Research laboratories and academic institutes
  • Venture capitalists and other government funding organizations
  • Research and consulting firms
  • Healthcare institutions (hospitals and diagnostic clinics)
  • Pharmaceutical and biotechnology companies
  • Academic and government research institutes
  • Life science companies

Report Objectives

  • To define, describe, and forecast the next-generation sequencing market based on offering, product type, platform technology, product workflow, product end user, service type, service workflow, service end user, application, and region
  • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall next-generation sequencing market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa
  • To profile key players in the global next-generation sequencing market and comprehensively analyze their platforms, reagents, kits, consumables, and service portfolios, market position, and core competencies
  • To track and analyze competitive developments such as product & service launches, expansions, agreements, and collaborations in the next-generation sequencing market
  • To benchmark players within the next-generation sequencing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and service strategy.

Available customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographical Analysis

  • Further breakdown of the Rest of Europe next-generation sequencing market, by country
  • Further breakdown of the Rest of Asia Pacific next-generation sequencing market, by country
  • Further breakdown of the Rest of Latin America next-generation sequencing market, by country
  • Further breakdown of the Rest of Middle East next-generation sequencing market, by country

Company Information

  • Detailed analysis and profiling of additional market players (up to five)

Segment Analysis

  • Further breakdown of the other application and other end users area into subsegments
  • Cross-segment analysis.

 

Get the Full Next-generation Sequencing Market Report

Full forecast, segment splits, and company analysis for all Next-generation Sequencing Market.

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
DMCA.com Protection Status